Updated: February 25, 2026
Baricitinib Shortage Update: What Patients Need to Know in 2026
Author
Peter Daggett

Summarize with AI
Is Baricitinib (Olumiant) in shortage in 2026? Get the latest update on availability, pricing, and what you can do if you can't find your prescription.
Baricitinib in 2026: Is There Still a Shortage?
If you rely on Baricitinib (Olumiant) for rheumatoid arthritis, alopecia areata, or another condition, you want to know one thing: can I get my medication?
Baricitinib experienced some supply disruptions in the past, particularly during 2020-2021 when demand spiked due to its emergency use for COVID-19 treatment. But what's the situation now? In this article, we'll give you the latest update on Baricitinib availability and what to do if you're having trouble finding it.
Is Baricitinib Still in Shortage?
As of February 2026, Baricitinib is not listed on the FDA drug shortage database. This means the FDA considers the overall market supply adequate to meet demand.
However, "not in shortage" doesn't mean "easy to find." Baricitinib is a specialty medication made by a single manufacturer (Eli Lilly), and it's not stocked at most retail pharmacies. So even though supply exists, accessing it can still be challenging for individual patients.
Why Can Baricitinib Still Be Hard to Find?
Even without an official shortage, patients report difficulty getting Baricitinib for several reasons:
- Specialty pharmacy requirements — most insurance plans require you to use a designated specialty pharmacy, not your local CVS or Walgreens
- Prior authorization delays — insurance companies require paperwork proving medical necessity, which can take days to weeks
- Step therapy mandates — you may need to try and fail other medications (like Methotrexate or a TNF inhibitor) before your insurer will approve Baricitinib
- No generic available — without generic competition, Eli Lilly is the sole source of supply in the US
For a deeper explanation, read our article on why Baricitinib is so hard to find.
How Much Does Baricitinib Cost in 2026?
Baricitinib remains a high-cost medication. Here's what you can expect to pay:
- Without insurance: $2,500 to $3,000 per month for a 30-day supply of Olumiant tablets
- With commercial insurance: Copays vary widely, but specialty tier medications often have copays of $100 to $500+ per month before any savings programs
- With the Olumiant Savings Card: As low as $5 per month for eligible commercially insured patients
- With patient assistance: $0 through the Lilly Cares Foundation for qualifying uninsured or underinsured patients
For detailed information on reducing your costs, see our guide to saving money on Baricitinib.
Are There New Options for Patients in 2026?
The JAK inhibitor landscape continues to evolve. While no generic Baricitinib is available yet, patients now have more treatment options than ever:
- Ritlecitinib (Litfulo) — approved in 2023 for severe alopecia areata, giving patients another option beyond Baricitinib for hair loss
- Upadacitinib (Rinvoq) — has expanded its approved indications and may be an option for RA patients who can't access Baricitinib
- Biosimilar TNF inhibitors — while not JAK inhibitors, biosimilar versions of Adalimumab (Humira) are now available at lower cost and may be suitable for some RA patients
Talk to your doctor about whether any of these options might work for you. Our alternatives guide covers the details.
How to Find Baricitinib in Stock
If you need Baricitinib right now, here are the most effective steps:
- Check Medfinder — search for real-time pharmacy availability in your area
- Contact your specialty pharmacy — if you don't know which one to use, call your insurance company's pharmacy benefits line
- Ask your doctor's office for help — many rheumatology and dermatology practices have staff who specialize in navigating specialty medication access
- Call Eli Lilly — the manufacturer can help connect you with available supply at 1-800-545-5979
For more tips, read our complete guide on how to find Baricitinib in stock near you.
Final Thoughts
The good news is that Baricitinib is not in shortage in 2026. The bad news is that specialty medication access in the US healthcare system remains complicated. Between insurance requirements, specialty pharmacy channels, and high costs, getting Baricitinib can feel like navigating a maze.
But with the right information and tools, you can get your medication. Start with Medfinder to check availability, explore savings programs, and work with your healthcare team to stay on track with your treatment.
Frequently Asked Questions
No. As of February 2026, Baricitinib (Olumiant) is not listed on the FDA drug shortage database. Supply from the manufacturer, Eli Lilly, appears stable. However, individual patients may still face access challenges due to specialty pharmacy requirements and insurance barriers.
Baricitinib experienced intermittent supply disruptions during 2020-2021, primarily because of increased demand when it received emergency use authorization for COVID-19 treatment. Supply has since stabilized.
As of 2026, no generic version of Baricitinib has been approved in the United States. Patent protections for Olumiant extend through the mid-to-late 2020s. When a generic becomes available, it could significantly reduce the cost of this medication.
First, check real-time availability on Medfinder (medfinder.com). Then contact your insurance company to find your designated specialty pharmacy. If needed, ask your doctor about alternative JAK inhibitors like Tofacitinib (Xeljanz) or Upadacitinib (Rinvoq).
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsRelated articles
29,697 have already found their meds with Medfinder.
Start your search today.

![Who Has Vyvanse in Stock Near You? Find It Today [2026]](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2Fvur4atr4%2Fproduction%2F1079f61f167dcbc2ed5f1da17a0dcb0b7166357e-1024x1024.png%3Frect%3D0%2C256%2C1024%2C512%26w%3D400%26h%3D200%26auto%3Dformat&w=828&q=75)



